← Back to Search

Omega-3 Fatty Acid

Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day for Cardiovascular Disease

N/A
Waitlist Available
Research Sponsored by Cardiovascular Research Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six weeks
Awards & highlights

Study Summary

The goal of the study is to test the efficacy of an EPA-enriched oil made by DuPont versus a DHA-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. This study will compare the efficacy of 1800 mg/day of EPA versus 1800 mg/day of DHA versus a fish oil product containing 1800 mg of EPA and 1200 mg of DHA/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. Safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. Efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.

Eligible Conditions
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio
Secondary outcome measures
LpPLA2

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Fish Oil with EPA 1800 mg/day and DHA 1200 mg/dayActive Control1 Intervention
Group II: DHA 1800 mg/dayActive Control1 Intervention
Group III: EPA 1800 mg/dayActive Control1 Intervention
Group IV: Olive Oil 6 grams/dayPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Cardiovascular Research AssociatesLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled
Dupont Applied BiosciencesIndustry Sponsor
11 Previous Clinical Trials
2,764 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~8 spots leftby Apr 2025